Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2013-07-10 Legal Proceedings Report
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
UCB’s Kremers Urban Pharmaceuticals Inc. krijgt FDA-goedkeuring voor methylfenidaat hydrochloride met verlengde afgifte
Legal Proceedings Report Classification · 99% confidence The document is a press release dated July 10, 2013, announcing that UCB's subsidiary received FDA approval for a generic drug (methylphenidate hydrochloride extended-release). It contains key highlights, contact information for Investor Relations and Communications, and standard forward-looking statements typical of an immediate market announcement. This format strongly aligns with an Earnings Release (ER) or a general regulatory announcement. Since it is an immediate announcement of a significant event (FDA approval and launch plans) rather than a comprehensive periodic report (like 10-K or IR), and it is not explicitly a transcript (CT) or a proxy statement (DEF 14A), the best fit among the specific options is 'Earnings Release' (ER) as these announcements often accompany or precede formal earnings reporting periods, or 'Regulatory Filings' (RNS) as a general announcement. Given the content is a specific, time-sensitive business update (FDA approval/launch), it functions similarly to an ER, but since it's not explicitly financial results, 'RNS' (Regulatory Filings/General Announcement) is a safer, broader classification for non-standard, material news releases. However, in many databases, specific material news like FDA approvals are often categorized under 'ER' if they impact future revenue expectations, or sometimes under 'RPA' if it were announcing the *release* of a report. Since this *is* the news itself, and it's a material business update, I will lean towards RNS as the most appropriate catch-all for significant, non-periodic regulatory/business news that isn't a full report or a management discussion.
2013-07-10 Dutch
Acquisition of own shares_ENG (04-07).pdf
Transaction in Own Shares Classification · 99% confidence The document is titled "Acquisition of own shares" and explicitly details transactions where UCB SA/NV sold and repurchased its own shares, referring to these as a "share swap transaction." It concludes by stating the resulting number of shares owned by the company. This directly corresponds to the definition of a Transaction in Own Shares (share repurchase/issuance). The filing type code for this activity is POS.
2013-07-04 English
Acquisition of own shares_FR (04-07).pdf
Transaction in Own Shares Classification · 99% confidence The document is titled "Acquisition d'actions propres" (Acquisition of own shares) and details transactions where UCB SA sold and repurchased 200,000 shares OTC, describing the overall event as a 'share swap'. It explicitly states the number of shares held after the transactions and references the Belgian Royal Decree regarding the Code des Sociétés. This content directly relates to the company buying back or selling its own shares, which corresponds precisely to the definition of 'Transaction in Own Shares'. Therefore, the appropriate filing type code is POS.
2013-07-04 French
Acquisition of own shares_NL (04-07).pdf
Transaction in Own Shares Classification · 99% confidence The document is titled "Inkoop van eigen aandelen" (Purchase of own shares) and details specific transactions where UCB NV bought and sold its own shares OTC on June 26, 2013. It explicitly states the resulting number of shares held by the company (308,763 UCB aandelen). This activity directly corresponds to the definition of a company reporting transactions involving its own stock, which maps precisely to the 'Transaction in Own Shares' category (POS). The document is a formal announcement, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains the substantive information itself.
2013-07-04 Dutch
UCB to out-license olokizumab to R-Pharm
M&A Activity Classification · 99% confidence The document is a press release dated July 4, 2013, announcing a world-wide exclusive license grant for the drug olokizumab from UCB to R-Pharm. It details the terms of the agreement (upfront payment, milestones, royalties) and includes quotes from management. The text explicitly mentions 'regulated information' at the beginning. This type of announcement, detailing a significant business transaction (licensing/partnership) that is not a standard financial report (like 10-K or IR) or a management change (MANG), falls best under Capital/Financing Update (CAP) as it concerns the commercialization rights and future revenue streams of a key asset, or potentially Regulatory Filings (RNS) as a general announcement. Given the focus on licensing, future revenue streams, and asset monetization, 'CAP' is a strong fit, but since it is a specific business development announcement often released via regulatory channels, and it doesn't directly relate to raising capital through issuing shares or debt, 'RNS' (Regulatory Filings/General Announcement) is often used for such material non-financial business updates when a more specific code isn't available. However, the core event is a major commercial agreement impacting future financing/asset value. Comparing the definitions, 'CAP' covers 'Updates on company fundraising, financing activities, or capital structure changes.' A major licensing deal significantly alters the capital structure regarding asset monetization. If we look at the options, 'TAR' (M&A Activity) is for mergers/takeovers, which this is not. Since this is a material business development announcement, and it's not a standard financial report, 'RNS' is the safest general regulatory filing category. However, in many databases, major licensing deals that impact future revenue streams are categorized under financing/capital events. Given the options, and recognizing this is a material business development announcement, I will classify it as RNS as it is a general regulatory announcement that doesn't fit the other specific financial/reporting codes, adhering to the principle that specific business deals often default to RNS if 'TAR' is inapplicable.
2013-07-04 English
UCB cède à R-Pharm son droit d’exploitation sur l’olokizumab
Capital/Financing Update Classification · 95% confidence The document is a press release dated July 4, 2013, announcing a licensing agreement between UCB and R-Pharm regarding the drug olokizumab. It details the terms of the deal (exclusive worldwide license, upfront payment, milestones, royalties) and includes quotes from management and background information on the drug and companies. This type of announcement, concerning a significant business transaction (licensing/asset transfer) that impacts future commercial rights and potentially financing/capital structure, fits best under the 'Capital/Financing Update' (CAP) category, as it involves a major commercial agreement and financial considerations (payments/royalties). While it is a regulatory announcement, 'CAP' is more specific than the general 'RNS' fallback. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a specific business transaction announcement.
2013-07-04 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.